Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | NPC1 | O15118 | 3/20 | 0.81 |
| ▸ | RAB9A | P51151 | 3/20 | 0.81 |
| ▸ | GLA | P06280 | 1/20 | 0.81 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.81 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.81 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.81 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.81 |
| ▸ | CBFB | Q13951 | 1/20 | 0.81 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384128 | 1.00 | KDM4E (0.81) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL18075701 | 0.90 | KDM4E (1.00) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL28647309 | 0.86 | MEN1 (0.60) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL4157750 | 0.85 | KDM4E (0.58) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL24527524 | 0.85 | MAPT (0.58) | KDM4EMEN1KMT2AMAPTNPC1 | |
| Proflavine SCHEMBL28425236 | 0.81 | KMT2A (0.72) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL24527534 | 0.81 | MEN1 (0.53) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL24527544 | 0.81 | TERT (0.60) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL24527584 | 0.80 | MEN1 (0.52) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL7168746 | 0.79 | MEN1 (0.58) | KDM4EMEN1KMT2AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250290918-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2025-09-18 | — | — | US | claimed |
| US-11796534-B2 | Methods for assessing cell surface glycosylation | JUNO THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-114324625-A | Oligosaccharide marker and application thereof in cubilose identification | 香港名贵中药检定中心有限公司 | 2022-04-12 | — | — | CN | claimed |
| WO-2022015162-A1 | QUANTITATIVE DETECTION OF REDUCING SUGARS | DUCARES B.V. (NL) | 2022-01-20 | — | — | WO | claimed |
| US-20210255173-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | claimed |
| EP-3610261-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | Juno Therapeutics, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| CN-110709700-A | Method for evaluating cell surface glycosylation | 朱诺治疗学股份有限公司 | 2020-01-17 | — | — | CN | claimed |
| WO-2018191723-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2018-10-18 | — | — | WO | claimed |
| WO-2015033743-A1 | METHOD FOR PREPARING LABELED SUGAR CHAIN SAMPLE | 住友ベークライト株式会社 (JP) | 2015-03-12 | — | — | WO | claimed |
| US-8828732-B2 | Method of labeling sugar chain | SUMITOMO BAKELITE CO., LTD. (JP) | 2014-09-09 | — | — | US | claimed |
| EP-2685263-A1 | SUGAR CHAIN FLUORESCENT LABELING METHOD | Sumitomo Bakelite Co., Ltd. (JP) | 2014-01-15 | — | — | EP | claimed |
| US-20130310552-A1 | SUGAR CHAIN FLUORESCENT LABELING METHOD | SUMITOMO BAKELITE CO., LTD. (JP) | 2013-11-21 | — | — | US | claimed |
| EP-2282209-B1 | METHOD FOR LABELLING SUGAR CHAINS | SUMITOMO BAKELITE CO (JP) | 2012-10-03 | — | — | EP | claimed |
| US-20110089033-A1 | METHOD OF PREPARING SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD OF ANALYZING SUGAR CHAIN | SUMITOMO BAKELITE CO., LTD. (JP) | 2011-04-21 | — | — | US | claimed |
| EP-2295962-A1 | METHOD FOR PREPARATION OF SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYSIS OF SUGAR CHAIN | Sumitomo Bakelite Co., Ltd. (JP) | 2011-03-16 | — | — | EP | claimed |
| US-20110046364-A1 | METHOD OF LABELING SUGAR CHAIN | SUMITOMO BAKELITE CO., LTD. (JP) | 2011-02-24 | — | — | US | claimed |
| EP-2282209-A1 | METHOD FOR LABELLING SUGAR CHAINS | Sumitomo Bakelite Company Limited (JP) | 2011-02-09 | — | — | EP | claimed |
| WO-2009150834-A1 | METHOD FOR PREPARATION OF SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYSIS OF SUGAR CHAIN | 住友ベークライト株式会社 (JP) | 2009-12-17 | — | — | WO | claimed |
| WO-2008130924-A2 | ISOTOPICALLY-LABELED GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-12545747-B2 | Method, kit, and device for preparing glycan from glycoprotein | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20250306030-A1 | METHODS FOR MASS SPECTROMETRY ANALYSIS OF ENGINEERED CELL COMPOSITIONS | JUNO THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250290918-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-12379375-B2 | Methods for assessing cell surface glycosylation | JUNO THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12366580-B2 | Methods for mass spectrometry analysis of engineered cell compositions | JUNO THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4421168-A2 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-3960854-B1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | HALOZYME INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118326524-A | Improved sugar chain library preparation method | 北京普利米特生物科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4269578-B1 | SOLUBLE HYALURONIDASE COMPOSITION | HALOZYME INC (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4062176-B1 | LABEL-FREE N-GLYCAN QUANTIFICATION METHODS | BRISTOL MYERS SQUIBB CO (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240159743-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4269578-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3896074-B1 | METHOD, KIT, AND DEVICE FOR PREPARING GLYCAN FROM GLYCOPROTEIN | AIST (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-11796534-B2 | Methods for assessing cell surface glycosylation | JUNO THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230323422-A1 | METHOD OF MAKING PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230313259-A1 | MANUFACTURING PROCESS FOR PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116583536-A | Method for producing protein | 百时美施贵宝公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116391043-A | Method for producing protein | 百时美施贵宝公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-4196598-A2 | METHOD OF MAKING PROTEIN | Bristol-Myers Squibb Company (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4196597-A2 | MANUFACTURING PROCESS FOR PROTEIN | Bristol-Myers Squibb Company (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230025648-A1 | LABEL-FREE N-GLYCAN QUANTIFICATION METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | US | disclosed |
| US-11491212-B1 | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B | CATALYST BIOSCIENCES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-115261425-A | Method, kit and apparatus for producing sugar chain of glycoprotein | 住友电木株式会社 | 2022-11-01 | — | — | CN | disclosed |
| EP-4062176-A1 | LABEL-FREE N-GLYCAN QUANTIFICATION METHODS | Bristol-Myers Squibb Company (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-114981659-A | Method for quantifying unmarked N-glycans | 百时美施贵宝公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114324625-A | Oligosaccharide marker and application thereof in cubilose identification | 香港名贵中药检定中心有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11293926-B2 | Method for preparing sugar chain | SUMITOMO BAKELITE CO., LTD. (JP) | 2022-04-05 | — | — | US | disclosed |
| EP-3960854-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20220050114-A1 | METHODS FOR MASS SPECTROMETRY ANALYSIS OF ENGINEERED CELL COMPOSITIONS | JUNO THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| WO-2022036275-A2 | MANUFACTURING PROCESS FOR PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036232-A2 | METHOD OF MAKING PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220017648-A1 | Method, Kit, and Device for Preparing Glycan from Glycoprotein | SUMITOMO BAKELITE CO., LTD. (JP) | 2022-01-20 | — | — | US | disclosed |
| WO-2022015162-A1 | QUANTITATIVE DETECTION OF REDUCING SUGARS | DUCARES B.V. (NL) | 2022-01-20 | — | — | WO | disclosed |
| EP-3663399-B1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11203749-B2 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3896074-A1 | METHOD, KIT, AND DEVICE FOR PREPARING GLYCAN FROM GLYCOPROTEIN | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2021-10-20 | — | — | EP | disclosed |
| CN-113383003-A | Method, kit and apparatus for producing sugar chain from glycoprotein | 国立研究开发法人产业技术综合研究所 | 2021-09-10 | — | — | CN | disclosed |
| US-20210255173-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210238260-A1 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | GC BIOPHARMA CORP. (KR) | 2021-08-05 | — | — | US | disclosed |
| WO-2021154414-A2 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | CATALYST BIOSCIENCES, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-3760715-B1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | HALOZYME INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210230570-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | GC BIOPHARMA CORP. (KR) | 2021-07-29 | — | — | US | disclosed |
| CN-113167796-A | Methods for performing mass spectrometry on engineered cell compositions | 朱诺治疗学股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3850366-A1 | METHODS FOR MASS SPECTROMETRY ANALYSIS OF ENGINEERED CELL COMPOSITIONS | Juno Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021102437-A1 | LABEL-FREE N-GLYCAN QUANTIFICATION METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-27 | — | — | WO | disclosed |
| US-10982203-B2 | Modified factor IX polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3760715-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020122072-A1 | METHOD, KIT, AND DEVICE FOR PREPARING GLYCAN FROM GLYCOPROTEIN | 国立研究開発法人産業技術総合研究所 | 2020-06-18 | — | — | WO | disclosed |
| EP-3663399-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | Catalyst Biosciences, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2020056047-A1 | METHODS FOR MASS SPECTROMETRY ANALYSIS OF ENGINEERED CELL COMPOSITIONS | JUNO THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-10578624-B2 | Determination of glycosaminoglycan levels by mass spectrometry | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3610261-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | Juno Therapeutics, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-110709700-A | Method for evaluating cell surface glycosylation | 朱诺治疗学股份有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-10317410-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190055534-A1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | OAKTREE FUND ADMINISTRATION, LLC | 2019-02-21 | — | — | US | disclosed |
| EP-3432000-A1 | METHOD FOR PREPARING SUGAR CHAIN | Sumitomo Bakelite Co., Ltd. (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-10183912-B2 | HDMX inhibitors and their use for cancer treatment | MiRx Pharmaceuticals, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-10160961-B2 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| WO-2018191723-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| EP-2877487-B1 | MODIFIED FACTOR X POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180245115-A1 | METHOD, KIT AND DEVICE FOR PREPARING GLYCOPROTEIN SUGAR CHAIN | SUMITOMO BAKELITE CO., LTD. (JP) | 2018-08-30 | — | — | US | disclosed |
| CN-108138207-A | Method, kit and apparatus for producing sugar chain of glycoprotein | 住友电木株式会社 | 2018-06-08 | — | — | CN | disclosed |
| US-9933432-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9856467-B2 | Modified factor X polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170350900-A1 | DETERMINATION OF GLYCOSAMINOGLYCAN LEVELS BY MASS SPECTROMETRY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| EP-3218722-A1 | DETERMINATION OF GLYCOSAMINOGLYCAN LEVELS BY MASS SPECTROMETRY | Shire Human Genetic Therapies, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170212129-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20160376577-A1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | OAKTREE FUND ADMINISTRATION, LLC | 2016-12-29 | — | — | US | disclosed |
| US-20160356783-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| EP-3096136-A1 | COMPOSITION, METHOD FOR PREPARING SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYZING SUGAR CHAIN | Sumitomo Bakelite Co.,Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160327568-A1 | COMPOSITION, METHOD FOR PREPARING SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYZING SUGAR CHAIN | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-11-10 | — | — | US | disclosed |
| US-9476037-B2 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9448147-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| EP-3064580-A1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | Catalyst Biosciences, Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160201047-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | GC BIOPHARMA CORP. (KR) | 2016-07-14 | — | — | US | disclosed |
| WO-2016077775-A1 | DETERMINATION OF GLYCOSAMINOGLYCAN LEVELS BY MASS SPECTROMETRY | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| EP-2679678-B1 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9328339-B2 | Modified factor IX polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2687596-B1 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES INC (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2281037-B1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | CATALYST BIOSCIENCES INC (US) | 2015-11-11 | — | — | EP | disclosed |
| WO-2015153535-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MiRx Pharmaceuticals, LLC (US) | 2015-10-08 | — | — | WO | disclosed |
| US-9145552-B2 | Modified factor X polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9085645-B2 | Sugar chain fluorescent labeling method | SUMITOMO BAKELITE CO., LTD. (JP) | 2015-07-21 | — | — | US | disclosed |
| EP-2877487-A1 | MODIFIED FACTOR X POLYPEPTIDES AND USES THEREOF | Catalyst Biosciences, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-2268805-B1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | HALOZYME INC (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2147096-B1 | Modified factor VII polypeptides and uses thereof | CATALYST BIOSCIENCES INC (US) | 2015-03-25 | — | — | EP | disclosed |
| WO-2015033743-A1 | METHOD FOR PREPARING LABELED SUGAR CHAIN SAMPLE | 住友ベークライト株式会社 (JP) | 2015-03-12 | — | — | WO | disclosed |
| EP-2136896-B1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20140322191-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | GC BIOPHARMA CORP. (KR) | 2014-10-30 | — | — | US | disclosed |
| US-8828732-B2 | Method of labeling sugar chain | SUMITOMO BAKELITE CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20140234290-A1 | MODIFIED FACTOR X POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES, INC. | 2014-08-21 | — | — | US | disclosed |
| US-8778870-B2 | Modified factor IX polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8703498-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140065716-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140044701-A1 | Factor VII polypeptides that are modified and uses thereof | OAKTREE FUND ADMINISTRATION, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140030247-A1 | Modified factor X polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. | 2014-01-30 | — | — | US | disclosed |
| WO-2014018120-A1 | MODIFIED FACTOR X POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| EP-2687596-A2 | Factor VII polypeptides that are modified and uses thereof | Catalyst Biosciences, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2685263-A1 | SUGAR CHAIN FLUORESCENT LABELING METHOD | Sumitomo Bakelite Co., Ltd. (JP) | 2014-01-15 | — | — | EP | disclosed |
| CN-101678079-B | Modified erythropoietin polypeptides and uses thereof for treatment | NAUTILUS BIOTECH S A | 2013-12-25 | — | — | CN | disclosed |
| EP-2674487-A2 | Large-scale production of soluble hyaluronidase | Halozyme, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20130310552-A1 | SUGAR CHAIN FLUORESCENT LABELING METHOD | SUMITOMO BAKELITE CO., LTD. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-20130243855-A1 | Modified coagulation factor IX polypeptides and use thereof for treatment | NAUTILUS BIOTECH, S.A. (FR) | 2013-09-19 | — | — | US | disclosed |
| EP-2635677-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | Catalyst Biosciences, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| US-8519103-B2 | Factor VII polypeptides that are modified and uses thereof | CATALYST BIOSCIENCES, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2120998-B1 | MODIFIED ERYTHROPOIETIN POLYPEPTIDES AND USES THEREOF FOR TREATMENT | HANALL BIOPHARMA CO LTD (KR) | 2013-08-07 | — | — | EP | disclosed |
| US-20130177541-A9 | Modified factor IX polypeptides and uses thereof | GC BIOPHARMA CORP. (KR) | 2013-07-11 | — | — | US | disclosed |
| US-8383388-B2 | for oral administration; exhibit increased protein stability; exhibit increased stability in the bloodstream, following oral administration, and/or under storage conditions | CATALYST BIOSCIENCES, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20130029365-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8343487-B2 | Large-scale production of soluble hyaluronidase | HALOZYME, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120308540-A1 | Modified factor IX polypeptides and uses thereof | MADISON EDWIN L (US) | 2012-12-06 | — | — | US | disclosed |
| US-8304250-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120264686-A9 | MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF | Hanall Biopharma Co. Ltd | 2012-10-18 | — | — | US | disclosed |
| EP-2282209-B1 | METHOD FOR LABELLING SUGAR CHAINS | SUMITOMO BAKELITE CO (JP) | 2012-10-03 | — | — | EP | disclosed |
| US-8252743-B2 | Modified erythropoietin polypeptides and uses thereof for treatment | HANALL BIOPHARMA CO., LTD. (KR) | 2012-08-28 | — | — | US | disclosed |
| US-20120196348-A1 | Large-scale production of soluble hyaluronidase | HALOZYME THERAPEUTICS, INC. | 2012-08-02 | — | — | US | disclosed |
| EP-2481797-A1 | Modified factor VII polypeptides and uses thereof | Catalyst Biosciences, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8187855-B2 | Large-scale production of soluble hyaluronidase | HALOZYME, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2012061654-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | CATALYST BIOSCIENCES, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120094906-A1 | MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF | Hanall Biopharma Co. Ltd | 2012-04-19 | — | — | US | disclosed |
| US-8148112-B2 | Sugar chain containing 4-position halogenated galactose and application thereof | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-2297197-B1 | MODIFIED ERYTHROPOIETIN (EPO)POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF | HANALL BIOPHARMA CO LTD (KR) | 2012-03-07 | — | — | EP | disclosed |
| EP-2423306-A1 | Modified coagulation factor IX polypeptides and use thereof for treatment | Catalyst Biosciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2423305-A1 | Modified coagulation factor IX polypeptides and use thereof for treatment | Catalyst Biosciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2423307-A1 | Modified coagulation factor IV polypeptides and use thereof for treatment | Catalyst Biosciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8092825-B2 | Glycan binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110213137-A1 | ISOTOPICALLY-LABELED GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110089033-A1 | METHOD OF PREPARING SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD OF ANALYZING SUGAR CHAIN | SUMITOMO BAKELITE CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2297197-A1 | MODIFIED ERYTHROPOIETIN (EPO)POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF | HanAll Biopharma Co., Ltd. (KR) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295962-A1 | METHOD FOR PREPARATION OF SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYSIS OF SUGAR CHAIN | Sumitomo Bakelite Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20110053247-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | HALOZYME, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110046364-A1 | METHOD OF LABELING SUGAR CHAIN | SUMITOMO BAKELITE CO., LTD. (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2281037-A2 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | Catalyst Biosciences, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-2282209-A1 | METHOD FOR LABELLING SUGAR CHAINS | Sumitomo Bakelite Company Limited (JP) | 2011-02-09 | — | — | EP | disclosed |
| EP-2268805-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100166729-A9 | Modified factor VII polypeptides and uses thereof | MADISON EDWIN L | 2010-07-01 | — | — | US | disclosed |
| US-20100151499-A1 | PROTEOLYTIC RELEASE OF GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100151584-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| CN-101678079-A | Modified erythropoietin polypeptides and uses thereof for treatment | NAUTILUS BIOTECH S A | 2010-03-24 | — | — | CN | disclosed |
| EP-2147096-A2 | MODIFIED FACTOR VII POLYPETIDES AND USES THEREOF | Catalyst Biosciences, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2136896-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | Momenta Pharmaceuticals, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009152944-A1 | MODIFIED ERYTHROPOIETIN (EPO)POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF | HANALL PHARMACEUTICAL CO., LTD (KR) | 2009-12-23 | — | — | WO | disclosed |
| EP-2135090-A1 | PROTEOLYTIC RELEASE OF GLYCANS | Momenta Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009150834-A1 | METHOD FOR PREPARATION OF SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYSIS OF SUGAR CHAIN | 住友ベークライト株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
| US-20090291890-A1 | Factor VII polypeptides that are modified and uses thereof | OAKTREE FUND ADMINISTRATION, LLC | 2009-11-26 | — | — | US | disclosed |
| EP-2120998-A2 | MODIFIED ERYTHROPOIETIN POLYPEPTIDES AND USES THEREOF FOR TREATMENT | Hanall Pharmaceutical Co., Ltd. (KR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009126307-A2 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | CATALYST BIOSCIENCES, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090238789-A1 | Modified erythropoietin polypeptides and uses thereof | HANALL BIOPHARMA CO., LTD. (KR) | 2009-09-24 | — | — | US | disclosed |
| WO-2009111066-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | HALOZYME, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-2084274-A2 | MODIFIED COAGULATION FACTOR IX POLYPEPTIDES AND USE THEREOF FOR TREATMENT | Nautilus Technology LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090098103-A1 | Modified factor VII polypeptides and uses thereof | CATALYST BIOSCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090060980-A1 | GLYCAN BINDING PROTEINS AS THERAPEUTIC TARGETS FOR RETINAL DISORDERS AND TREATMENT METHODS BASED THEREON | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-03-05 | — | — | US | disclosed |
| US-20090018327-A1 | SUGAR CHAIN CONTAINING 4-POSITION HALOGENATED GALACTOSE AND APPLICATION THEREOF | NATIONAL UNIVERSITY CORP. HOKKAIDO UNIVERSITY (JP) | 2009-01-15 | — | — | US | disclosed |
| WO-2008130924-A2 | ISOTOPICALLY-LABELED GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008127702-A2 | MODIFIED FACTOR VII POLYPETIDES AND USES THEREOF | CATALYST BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008128220-A1 | PROTEOLYTIC RELEASE OF GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008128225-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008121768-A2 | GLYCAN-BINDING PROTEINS AS THERAPEUTIC TARGETS FOR RETINAL DISORDERS AND TREATMENT METHODS BASED THEREON | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008065372-A2 | MODIFIED ERYTHROPOIETIN POLYPEPTIDES AND USES THEREOF FOR TREATMENT | NAUTILUS BIOTECH, S.A. (FR) | 2008-06-05 | — | — | WO | disclosed |
| US-20080102115-A1 | Modified coagulation factor IX polypeptides and use thereof for treatment | GC BIOPHARMA CORP. (KR) | 2008-05-01 | — | — | US | disclosed |
| WO-2007149406-A2 | MODIFIED COAGULATION FACTOR IX POLYPEPTIDES AND USE THEREOF FOR TREATMENT | NAUTILUS TECHNOLOGY LLC (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20060172339-A1 | Particle-based multiplex assay for identifying glycosylation | PERKINELMER LAS, INC. (US) | 2006-08-03 | — | — | US | disclosed |
| US-20060172339-A1 | Particle-based multiplex assay for identifying glycosylation | PERKINELMER LAS, INC. (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (23 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018327-A1 | SUGAR CHAIN CONTAINING 4-POSITION HALOGENATED GALACTOSE AND APPLICATION THEREOF | GALK1, GALE, UGGT1 | KDM4E 1794/4885MEN1 4764/4885KMT2A 1483/4885 |
| US-10317410-B2 | Multi-dimensional chromatographic methods for separating N-glycans | FUT5, B3GNT2, ENGASE | KDM4E 3791/4885MEN1 1571/4885KMT2A 3520/4885 |
| US-20140030247-A1 | Modified factor X polypeptides and uses thereof | F13B, F11, F10 | KDM4E 3961/4885MEN1 1203/4885KMT2A 3855/4885 |
| US-20120308540-A1 | Modified factor IX polypeptides and uses thereof | F9, F13B, F8 | KDM4E 1905/4885MEN1 2232/4885KMT2A 1870/4885 |
| US-20160201047-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | F9, F13B, F13A1 | KDM4E 1598/4885MEN1 2505/4885KMT2A 1038/4885 |
| US-10160961-B2 | Factor VII polypeptides that are modified and uses thereof | F7, F13B, HABP2 | KDM4E 3937/4885MEN1 1713/4885KMT2A 2351/4885 |
| US-20190055534-A1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | F7, F13B, HABP2 | KDM4E 3907/4885MEN1 1694/4885KMT2A 2318/4885 |
| US-20110046364-A1 | METHOD OF LABELING SUGAR CHAIN | SLC2A2, FUT6, SLC2A1 | KDM4E 2891/4885MEN1 3316/4885KMT2A 2528/4885 |
| US-20080102115-A1 | Modified coagulation factor IX polypeptides and use thereof for treatment | F9, F13B, F13A1 | KDM4E 2699/4885MEN1 2412/4885KMT2A 3311/4885 |
| US-20210238260-A1 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | F13B, F9, F13A1 | KDM4E 3368/4885MEN1 2092/4885KMT2A 1705/4885 |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | TP53, DDX3X, API5 | KDM4E 809/4885MEN1 2446/4885KMT2A 1544/4885 |
| US-20130177541-A9 | Modified factor IX polypeptides and uses thereof | F9, F13B, F8 | KDM4E 1905/4885MEN1 2232/4885KMT2A 1870/4885 |
| US-20090291890-A1 | Factor VII polypeptides that are modified and uses thereof | F7, HABP2, F13B | KDM4E 4188/4885MEN1 1834/4885KMT2A 3544/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | KDM4E 3316/4885MEN1 4843/4885KMT2A 1905/4885 |
| US-10183912-B2 | HDMX inhibitors and their use for cancer treatment | TP53, MDM4, MDM2 | KDM4E 839/4885MEN1 2156/4885KMT2A 1514/4885 |
| US-10982203-B2 | Modified factor IX polypeptides and uses thereof | F9, F13B, F13A1 | KDM4E 1598/4885MEN1 2505/4885KMT2A 1038/4885 |
| US-11203749-B2 | Factor VII polypeptides that are modified and uses thereof | F7, F13B, HABP2 | KDM4E 3907/4885MEN1 1694/4885KMT2A 2318/4885 |
| US-20160376577-A1 | FACTOR VII POLYPEPTIDES THAT ARE MODIFIED AND USES THEREOF | F7, F13B, HABP2 | KDM4E 3937/4885MEN1 1713/4885KMT2A 2351/4885 |
| US-20110213137-A1 | ISOTOPICALLY-LABELED GLYCANS | FUT5, FUT6, ST3GAL3 | KDM4E 2712/4885MEN1 2807/4885KMT2A 3229/4885 |
| US-11491212-B1 | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B | F13B, F13A1, F9 | KDM4E 2231/4885MEN1 2451/4885KMT2A 898/4885 |
| US-20210230570-A1 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | F9, F13B, F8 | KDM4E 1605/4885MEN1 2271/4885KMT2A 1181/4885 |
| US-20140234290-A1 | MODIFIED FACTOR X POLYPEPTIDES AND USES THEREOF | F13B, F11, F10 | KDM4E 3961/4885MEN1 1203/4885KMT2A 3855/4885 |
| US-12545747-B2 | Method, kit, and device for preparing glycan from glycoprotein | FUT7, FUT4, SIGLEC7 | KDM4E 1909/4885MEN1 2730/4885KMT2A 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.